Cat. #

Product

Size

Price

License

Quantity

Details

0027VCT

rLV.EF1.Tet3G-9

3 x 20 uL

USD $2177.00

License Statement

ID Number
42	Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent # 8383364, # 9181556 , European patents EP # 1954811, #2352833 and corresponding patent claims outside these regions which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to any data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Takara Bio USA, Inc. is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to TET Systems. For license information, please contact: GSF/CEO TET Systems GmbH & Co. KG, Im Neuenheimer Feld 582 69120 Heidelberg Germany Tel: +49 6221 5880400 Fax: +49 6221 5880404 email: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/ip-licensing/licensing/for-profit-research
262	Vectalys Technology Vectalys’ highly concentrated and purified lentiviral vectors and its use are covered by U.S. Patent No. 13/0029379 and WO 2013/014537. The purchase price of this product includes limited, nontransferable rights to use this product solely for internal research purposes. Academic and not-for-profit research institutions whose research using the Vectalys’ Technology or the product obtained by the Vectalys’ technology when sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from Vectalys in order to use the Vectalys’ Technology or the product obtained by the Vectalys’ technology. Please contact Vectalys for information on purchasing a license to use these products for commercial purposes: Parc Technologique du Canal, Bâtiment Canal Biotech II, 3, rue des satellites, 31400 Toulouse (France), TEL: +33(0)5 61 28 70 75, EMAIL: sandy.darrigan@vectalys.com.
353	LentiFlash Technology: This product is covered by the French pending patent application FR1554381 and the PCT application PCT/FR/051152. The purchase price of this product includes limited, nontransferable rights to use this product solely for internal research purposes. Please contact Vectalys for information on purchasing a license to use these products for commercial purposes: Parc Technologique du Canal, Bâtiment Canal Biotech II, 3, rue des satellites, 31400 Toulouse (France), TEL: +33(0)5 61 28 70 75, EMAIL: sandy.darrigan@vectalys.com.

The Flash Therapeutics Inducible Reprogramming Lentiviral Vectors are prepackaged lentiviral particles expressing polycistronic Oct4, Sox2, KLF4, and Myc for reprogramming human somatic cells under the induction of doxycycline using Tet technology. These VSV-G pseudotyped viruses are capable of infecting both dividing and non-dividing cells. The high purification level of these lentiviral particles allows transduction of primary cells and immortalized cell lines without inducing any toxicity to the cells, even at high multiplicity of infection (M.O.I.). The expression of these four factors has been shown to reprogram a variety of differentiated cells into induced pluripotent stem (iPS) cells with embryonic stem (ES) cell-like properties.

631132

TetR Monoclonal Antibody (Clone 9G9)

200 ug

USD $467.00

Monoclonal antibody produced from mouse hybridoma cells against the wild-type bacterial Tet repressor (TetR). It can be used for detecting TetR-containing proteins on Western blots, and for testing or screening cell lines expressing the Tet-On Advanced, Tet-Off Advanced, or Tet-Off transactivators. It is not recommended for cell lines expressing the original Tet-On or Tet-tTS proteins.

Recommended Products